ERBB2 and carcinoma: In breast cancer, TP53 mutations have been shown to be most prevalent in the poor-prognosis basal-like or triple negative breast cancer (TNBC) subtype (80%), followed by HER2-positive cancers (72%), while mutation rates in the lower proliferative, less aggressive luminal carcinomas are rather low (12-29%) [5].